Quantinno Capital Management LP Grows Stake in Vir Biotechnology, Inc. $VIR

Quantinno Capital Management LP lifted its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 144.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,927 shares of the company’s stock after acquiring an additional 56,655 shares during the quarter. Quantinno Capital Management LP owned 0.06% of Vir Biotechnology worth $860,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in VIR. Raymond James Financial Inc. purchased a new stake in shares of Vir Biotechnology during the second quarter worth approximately $35,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Vir Biotechnology by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after buying an additional 1,390 shares during the last quarter. UMB Bank n.a. lifted its stake in Vir Biotechnology by 1,418.7% during the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after purchasing an additional 6,597 shares in the last quarter. CWM LLC lifted its stake in Vir Biotechnology by 23.0% during the 4th quarter. CWM LLC now owns 8,804 shares of the company’s stock worth $53,000 after acquiring an additional 1,646 shares in the last quarter. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in Vir Biotechnology during the 4th quarter worth approximately $60,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on VIR shares. HC Wainwright restated a “buy” rating on shares of Vir Biotechnology in a research note on Monday, August 10th. Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Leerink Partners upped their price objective on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a report on Wednesday, July 8th. Finally, Morgan Stanley set a $25.00 target price on Vir Biotechnology in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.62.

Vir Biotechnology Stock Up 1.6%

VIR opened at $9.39 on Tuesday. Vir Biotechnology, Inc. has a 52-week low of $4.25 and a 52-week high of $11.66. The company has a market cap of $1.59 billion, a P/E ratio of -5.05 and a beta of 1.66. The company has a 50 day moving average of $9.32 and a two-hundred day moving average of $9.14.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.14. The company had revenue of $238.95 million for the quarter, compared to analysts’ expectations of $135.88 million. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The firm’s quarterly revenue was up 19582.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.80) earnings per share. Research analysts anticipate that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current year.

Insider Transactions at Vir Biotechnology

In related news, Director Janet Napolitano sold 3,200 shares of Vir Biotechnology stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.45, for a total transaction of $30,240.00. Following the sale, the director owned 21,216 shares of the company’s stock, valued at $200,491.20. The trade was a 13.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is owned by company insiders.

Vir Biotechnology Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.